Similarly, Bruton’s tyrosine kinase (BTK) inhibitors have been useful in the treatment of NF-κB-positive DLBCL [113] as BTK is required for the BCR–NF-κB pathway in B cells. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.